A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-65
SponsorVanda Pharmaceuticals
About this trial
The goal of this study is to measure the effects of using Tradipitant to treat nausea and vomiting induced by GLP-1R agonist use in adults with class I or class II obesity, or adults who are overweight with at least one weight-related condition. The study is placebo-controlled with two treatment arms.
Eligibility criteria
Qualifiers
Body Mass Index ≥ 25 and < 40 kg/m²
No serious medical problems or chronic diseases, specifically no type I or type II diabetes
Disqualifiers
Another disorder that contributes to gastrointestinal symptoms
History of intolerance and/or hypersensitivity to NK-1 receptor antagonists
History of intolerance and/or hypersensitivity to GLP-1 receptor agonists
Exposure to any investigational medication within the past 60 days
Trial design
Treatments tested in this trial
- Tradipitant
- Placebo
Treatment groups
280 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov